Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

czyli wszystkie giełdy bardziej rozwinięte niż GPW
slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 19 lip 2022 14:59

Johnson & Johnson (NYSE:JNJ)'s pharmaceuticals unit, its largest, has reported strong results for the last few quarters, even as delayed surgical procedures crimped sales growth at the company's medical devices unit during the pandemic.

Double-digit growth in sales of cancer drug Darzalex and Crohn's disease drug Stelara helped J&J beat estimates for second-quarter profit.

Total sales rose about 3% to $24.02 billion, with nearly half of the sales coming from outside the United States. Analysts had expected sales of $23.77 billion, according to IBES data from Refinitiv.

On an adjusted basis, the company earned $2.59 per share, beating estimates of $2.54 per share.

Sales of the drug Stelara jumped 14.3% to $2.60 billion, while Darzalex revenue rose nearly 40% to $1.99 billion.

J&J's COVID-19 vaccine, which has seen weak demand and slow uptake, brought in $544 million in sales in the reported quarter.

Medical devices sales fell 1.1% to $6.90 billion, partly due to lockdowns in China.

J&J now expects full-year adjusted profit of $10.00 to $10.10 per share, compared with its prior forecast of $10.15 to $10.35.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

REKLAMA


slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 12 sie 2022 12:21

(Reuters) - Johnson & Johnson (NYSE:JNJ) will stop selling talc-based baby powder globally in 2023, the drugmaker said on Thursday, more than two years after it ended U.S. sales of a product that drew thousands of consumer safety lawsuits.

"As part of a worldwide portfolio assessment, we have made the commercial decision to transition to an all cornstarch-based baby powder portfolio," it said, adding that cornstarch-based baby powder is already sold in countries around the world.

In 2020, J&J announced that it would stop selling its talc Baby Powder in the United States and Canada because demand had fallen in the wake of what it called "misinformation" about the product's safety amid a barrage of legal challenges.

The company faces about 38,000 lawsuits from consumers and their survivors claiming its talc products caused cancer due to contamination with asbestos, a known carcinogen.

J&J denies the allegations, saying decades of scientific testing and regulatory approvals have shown its talc to be safe and asbestos-free. On Thursday, it reiterated the statement as it announced the discontinuation of the product.

J&J spun off subsidiary LTL Management in October, assigned its talc claims to it and immediately placed it into bankruptcy, pausing the pending lawsuits. Those suing have said Johnson & Johnson should have to defend itself against the lawsuits, while defendants of J&J and the bankrupt subsidiary process say it is an equitable way to compensate claimants.

Ben Whiting, an attorney with the plaintiffs firm Keller Postman, said because the lawsuits are paused in bankruptcy, the company’s sales decision won’t immediately impact them. But if a federal appellate court allows the cases to move forward, the consumers could try to use Johnson & Johnson’s decision to pull the products as evidence, Whiting said.

“If these cases were to go again, then it’s a very big deal,” Whiting said.

Before the bankruptcy filing, the company faced costs from $3.5 billion in verdicts and settlements, including one in which 22 women were awarded a judgment of more than $2 billion, according to bankruptcy court records.

A shareholder proposal calling for an end to global sales of the talc baby powder failed in April.

A 2018 Reuters investigation https://reut.rs/2QevfW1 found that J&J knew for decades that asbestos, a carcinogen, was present in its talc products. Internal company records, trial testimony and other evidence showed that from at least 1971 to the early 2000s, J&J's raw talc and finished powders sometimes tested positive for small amounts of asbestos.

In response to evidence of asbestos contamination presented in media reports, in the court room and on Capitol Hill, J&J has repeatedly said its talc products are safe, and do not cause cancer.

Sold since 1894, Johnson's Baby Powder became a symbol of the company's family-friendly image. An internal J&J marketing presentation from 1999 refers to the baby products division, with Baby Powder at the core, as J&J's "#1 Asset", Reuters reported, although the baby powder accounted for only about 0.5% of its U.S. consumer health business when the company pulled it off the shelves.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 06 paź 2022 07:26

(Reuters) -A U.S. bankruptcy judge has blocked New Mexico and Mississippi from pursuing lawsuits accusing Johnson & Johnson (NYSE:JNJ) of misleading consumers about the safety of its talc products, such as its baby powder, for now.

U.S. Bankruptcy Judge Michael Kaplan in Trenton, New Jersey on Tuesday said the litigation must be paused while an appellate court reviews whether J&J can use the bankruptcy of subsidiary LTL Management to resolve claims it is facing alleging that its talc products caused cancer. He said he would revisit allowing the states' lawsuits to proceed at a hearing in December.

J&J, which maintains its talc products are safe, created and spun off LTL in October, assigned its talc liabilities to the unit and placed it in bankruptcy a few days later.

That restructuring strategy, known as the "Texas two-step," paused about 38,000 individual lawsuits J&J was facing alleging that its baby powder and other talc-based products contain trace amounts of asbestos and caused mesothelioma and ovarian cancer.

"We disagree with Judge Kaplan's ruling and remain committed to ensuring that those companies that have knowingly harmed consumers for decades do not hide behind bankruptcy laws," New Mexico Attorney General Hector Balderas said in a statement.

The office Mississippi Attorney General Lynn Fitch and J&J did not respond to requests for comment.

LTL sued New Mexico and Mississippi in July after learning that the states intended to proceed with their lawsuits, despite the bankruptcy court's order in February pausing other talc litigation.

New Mexico and Mississippi had argued that the February order only blocked lawsuits by private plaintiffs and that Kaplan does not have the authority to block states from enforcing their consumer protection laws.

An ad hoc group of 41 states and the District of Columbia backed New Mexico and Mississippi in a written brief. Unlike with the private plaintiffs, allowing states to litigate would not risk opening the doors to copycat lawsuits that could disrupt LTL's bankruptcy restructuring, according to the states.

Attorneys representing private plaintiffs also supported the New Mexico and Mississippi lawsuits, saying they could provide clarity about the value of states' claims and aid in settlement negotiations.

The private plaintiffs have asked the Philadelphia-based 3rd U.S. Circuit Court of Appeals to dismiss LTL's bankruptcy, saying that LTL is a "concocted" corporation set up solely to stop them from getting their day in court.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 08 lis 2022 13:04

Spółka Johnson & Johnson (NYSE: JNJ) powiedziała we wtorek, że osiągnęła porozumienie w sprawie zakupu producenta pomp serca Abiomed (NASDAQ: ABMD) za 16,6 mld USD w gotówce, ponieważ ma na celu zwiększenie wzrostu w swoim dziale urządzeń medycznych po planowanym na przyszły rok wydzieleniu swojej działalności w zakresie zdrowia konsumentów. J&J zgodziła się zapłacić 380 USD za akcję Abiomedu, co stanowi wartość o 50,7% wyższą w stosunku do poniedziałkowej ceny zamknięcia wynoszącej 252,08 USD. Udziałowcy Abiomedu uzyskają również prawo do otrzymania do 35 USD za akcję w gotówce, jeśli zostaną osiągnięte pewne komercyjne i kliniczne kamienie milowe. Prezes J&J Joaquin Duato powiedział: „To przejęcie jest zgodne ze strategią rozszerzania działu medtech J&J na rynki o wysokim wzroście i przyspieszania wzrostu przychodów przy jednoczesnym postępie w zakresie standardów opieki”. Oczekuje się, że transakcja zostanie sfinalizowana przed końcem pierwszego kwartału 2023 roku i przyczyni się do skorygowanych zysków J&J od 2024 roku. W południe akcje Abiomedu podskoczyły o 50,25%.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 09 gru 2022 11:07

Will Johnson & Johnson Be a Better Buy After Spinning Off Its Consumer Business?

https://www.fool.com/investing/2022/01/ ... aI2lQIXZdU
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 04 sty 2023 23:36

Reuters - Johnson & Johnson (NYSE:JNJ)'s consumer health unit Kenvue on Wednesday filed with the U.S. securities regulator to be listed as an independent company in the United States, as part of its planned spin-off from the healthcare conglomerate.

The business houses Band-Aid bandages and Tylenol medicines and generated revenues of $15.1 billion in net sales in 2021, according to the S-1 filing.

The unit has faced nearly 40,000 lawsuits alleging its baby powder and other talc products contained asbestos later linked to mesothelioma and ovarian cancer in women who used it for personal hygiene, which J&J has denied.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 22 sty 2023 12:49

There are few companies out there with an unblemished track record of annual dividend increases that also have pristine financials to ensure that the dividend raises will continue.

Johnson & Johnson (NYSE: JNJ) is unquestionably one of them.

The company has raised its dividend annually since it began paying one in 1972. Last year marked the 50th year in a row that the drug and consumer products company lifted the dividend.


That’s what you call an impressive track record.
...
https://dailytradealert.com/2023/01/05/ ... slam-dunk/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 24 sty 2023 15:50

Latest Release
Jan 24, 2023

EPS / Forecast
2.35 / 2.24

Revenue / Forecast
23.7B / 23.9B

(Reuters) - Johnson & Johnson (NYSE:JNJ) on Tuesday said it sees the impact from high inflation carrying into 2023 and expects China's major COVID-19 outbreak to dent sales at its medical devices unit in the first half of the year.

https://www.investing.com/news/stock-ma ... it-2986660
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 13 lut 2023 17:55

(Reuters) - Alcon (NYSE:ALC) Vision LLC will pay Johnson & Johnson (NYSE:JNJ)'s J&J Surgical Vision Inc $199 million to settle legal battles over intellectual property related to the companies' laser eye-surgery devices, Alcon said in a press release on Sunday.

Alcon said the one-time payment would resolve "various worldwide intellectual property disputes" and that the companies had reached a cross-licensing agreement.

Representatives for Johnson & Johnson did not immediately respond to a request for comment Monday on the settlement.

A copyright trial was set to begin this week in Delaware federal court over claims that Alcon stole software from J&J's iFS Laser system, used for LASIK vision correction and other surgeries, and utilized it in Alcon's LenSx system to treat cataracts. A J&J expert had argued that the company was entitled to at least $3.1 billion in damages.

Both companies also accused each other of patent infringement in claims that had been put on hold by the Delaware court.

New Brunswick (NYSE:BC), New Jersey-based J&J's Catalys laser cataract surgery system competes with LenSx.

AMO Development LLC, which J&J acquired in 2017, sued Alcon in 2020 for allegedly stealing thousands of lines of its source code. It accused Alcon in a 2021 court filing of committing "theft and deception on a grand and shocking scale - of the type usually found in paperback novels and Hollywood movies, not real-life disputes between publicly traded companies."

J&J said Alcon left "smoking guns" in its code that showed its theft, like typographical errors identical to those in J&J's code and comments dating from before LenSx development started.

U.S. District Judge Colm Connolly said during a 2021 hearing that there was "overwhelming" evidence that Alcon intentionally copied J&J's code.

Fort Worth, Texas-headquartered Alcon had denied the allegations.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 22 mar 2023 20:08

J&J to seek U.S. Supreme Court review on unit's bankruptcy

(Reuters) - Johnson & Johnson (NYSE:JNJ) said on Wednesday that it would ask the U.S. Supreme Court to revive its effort to resolve tens of thousands of lawsuits over its talc products through the bankruptcy of a subsidiary, after an appeals court refused to reconsider its ruling that the bankruptcy was improper.

J&J sought to use the bankruptcy of its subsidiary company, LTL Management, to halt more than 38,000 lawsuits alleging the company’s Baby Powder and other talc products are contaminated with asbestos, which J&J denies.

J&J maintains its consumer talc products are safe and confirmed through thousands of tests to be asbestos-free.

The bankruptcy strategy stumbled in January, when the 3rd U.S. Circuit Court of Appeals based in Philadelphia ruled that LTL's bankruptcy should be dismissed because neither LTL nor J&J had a legitimate need for bankruptcy protection because they were not in "financial distress."

LTL Management asked the 3rd Circuit to reconsider its decision, a request the court unanimously rejected in a two-page ruling on Wednesday.

Leigh O'Dell, one of the lead attorneys representing plaintiffs in the lawsuits, said the 3rd Circuit's ruling is another step toward ending Johnson & Johnson's "attempted abuse of the bankruptcy system."

J&J said Wednesday that it would ask the 3rd Circuit to pause the ruling from taking effect to allow the company time to appeal to the Supreme Court.

The judge overseeing LTL's bankruptcy case, U.S. Bankruptcy Judge Michael Kaplan in Trenton, New Jersey, said in February that he was prepared to end the bankruptcy and allow talc lawsuits to resume once the 3rd Circuit issues a formal mandate of its January decision.

Before the bankruptcy filing, the company faced costs from $3.5 billion in verdicts and settlements, including one in which 22 women were awarded a judgment of more than $2 billion, according to bankruptcy court records.

J&J announced in 2020 that it would stop selling its talc Baby Powder in the United States and Canada due to what it called "misinformation" about the product's safety and later announced its intent to discontinue the product worldwide in 2023.

https://www.investing.com/news/stock-ma ... cy-3036872
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 05 kwie 2023 14:07

J&J ureguluje roszczenia dotyczące talku za 8,9 mld USD

J&J zapłaci 8,9 miliarda dolarów, aby zakończyć wszystkie procesy sądowe związane z rakiem związane z proszkami na bazie talku. Sfinansuje również fundusz powierniczy na pokrycie przyszłych roszczeń. Firma J&J zaprzestała produkcji tych pudrów, w tym zasypek dla niemowląt i pod prysznic.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 08 kwie 2023 20:31

The New York Times: Amerykański gigant słono zapłaci
W ramach ugody z ofiarami Johnson & Johnson zapłaci niespełna 9 mld dolarów.

Johnson & Johnson zawarł ugodę z tysiącami osób w sprawie sprzedaży talku, który okazał się być rakotwórczy. Wartość ugody opiewa na 8,9 mld dolarów.

Wspomniana kwota będzie wypłacona w ciągu następnych 25 lat. – Jest to zwycięstwo dla dziesiątek tysięcy kobiet, które zachorowały na nowotwór po skorzystaniu z produktów marki – stwierdzili prawnicy pozywających. Jak wynikało z dokumentów, o wadach produktu firma miała wiedzieć od dekad.

https://www.parkiet.com/gospodarka-swia ... no-zaplaci
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 19 kwie 2023 00:12

Latest Release
Apr 18, 2023

EPS / Forecast
2.68 / 2.5

Revenue / Forecast
24.7B / 23.61B

(Reuters) - Johnson & Johnson (NYSE:JNJ) on Tuesday cautioned investors over the lingering impact of inflation-driven costs this year as the healthcare conglomerate issued a conservative full-year profit forecast, and its shares fell more than 2%.

J&J also said it expected a steep decline in sales of its blockbuster Crohn's disease drug Stelara once it loses U.S. patent protection in late 2023.

Shares were 2.4% lower at $161.71, making it the biggest decliner on the Dow Jones Industrial Average index, which was off about 0.4%.

J&J, the first large drugmaker and medical device manufacturer to report earnings, raised the midpoint of its full-year profit forecast by 10 cents despite beating first-quarter estimates by 18 cents.

The company was "responsibly optimistic" about 2023, Chief Financial Officer Joseph Wolk said on a conference call, pointing to fierce competition for cancer drug Imbruvica and inflation as some of the challenges it was facing.

"Inflation is always a concern and we think that it's going to linger for the next couple of quarters," Edward Jones analyst John Boylan said. "It may take a while perhaps on the device side to work through some of the higher input costs, but we think that the healing process is in place."

A recovery in medical procedures after being weighed down by hospital staffing shortages helped the medical device unit post sales of $7.48 billion, topping analysts' estimates of $7.31 billion.

The company reported overall sales of $24.7 billion for the quarter, but posted a net loss of $68 million due to a $6.9 billion charge related to a second bankruptcy filing by its LTL Management unit as it attempts to settle more than 38,000 lawsuits claiming its talc products cause cancer. The company has said the products are safe and do not cause cancer.

J&J said the ongoing spinoff of its consumer health unit would not be impacted by the bankruptcy filing.

First-quarter sales at its pharmaceuticals unit was boosted by better-than-expected revenue from its COVID-19 vaccine and by Stelara, with sales of $2.44 billion that beat Wall Street expectations of $2.41 billion.

GRAPHIC - Sales of J&J's blockbuster Stelara

https://www.reuters.com/graphics/JOHNSO ... /chart.png

Prostate cancer treatment Erleada with sales of $542 million also exceeded estimates of $500 million, while sales of multiple myeloma treatment Darzalex were in line at $2.26 billion.

Sales of $747 million for the COVID vaccine that failed to gain much traction in the U.S. blew past diminished analysts' estimates of $50 million.

Consumer health sales rose 7.4% to $3.85 billion, surpassing estimates of $3.62 billion, powered by price hikes to offset the impact from inflation.

On an adjusted basis, the company posted first-quarter earnings of $2.68 per share, beating estimates of $2.50 according to Refinitiv data.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 24 kwie 2023 13:10

Johnson & Johnson hikes dividend, beats Q1 & raises outlook
Johnson & Johnson (NYSE:JNJ) hiked its dividend by 5.3% to $1.19 per share, or $4.76 annualized, for an annual yield of 2.9%.

The dividend will be payable on June 6, 2023, to stockholders of record on May 23, 2023, with an ex-dividend date of May 22, 2023.

The company reported its Q1 results on Tuesday, with both EPS of $2.68 and revenue of $24.7B beating expectations. Furthermore, the company raised its 2023 outlook, expecting EPS of $10.60-$10.70 and revenue of $97.9-98.9B, both above the consensus estimates.

Shares closed the week with a nearly 2% loss.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Johnson & Johnson J&J NYSE: JNJ leki, medycyna i kosmetyki

Postautor: slayer74 » 24 kwie 2023 13:21

Johnson & Johnson's Kenvue valued at nearly $40B ahead of IPO - WSJ

Johnson & Johnson (NYSE:JNJ) is due to start pitching shares of its consumer-healthcare business, Kenvue, early this week, the Wall Street Journal reported yesterday.

The healthcare giant seeks to raise $3.5 billion or more at a valuation close to $40B, the report added. After several days of investor meetings, Kenvue is likely to make its trading debut soon on the New York Stock Exchange under the ticker KVUE.

Kenvue is home to popular products like Tylenol, Band-Aids, Baby Shampoo, Aveeno, and Neutrogena. The company generated 15.7% of JNJ’s total revenue in 2022.

Kenvue’s IPO would mark the largest U.S. IPO since Intel (NASDAQ:INTC) spun off its self-driving car unit Mobileye (NASDAQ:MBLY) in 2022.

Johnson & Johnson shares are up half a percent in premarket Monday.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!


Wróć do „Zagranica”

REKLAMA

Kto jest online

Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 19 gości